Latest From Invuity Inc.
Just weeks after inking a billion-dollar acquisition of K2M, Stryker has announced a $190m deal to acquire photonics firm Invuity. Under the terms of the agreement, a subsidiary of Stryker will purchase all outstanding shares of Invuity for $7.40 per share in cash.
This week’s roundup includes high-level appointments by Almirall, Hookipa Biotech and RXi Pharmaceuticals, in addition to CEO appointments by Karolinska Development and ReForm Biologics and various board announcements by companies including Faron and Redx.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in March 2017.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Medical Device Deals Update column is a survey of recent medtech M&A, alliance, and financing activity. This month’s column covers deals announced May-June 2015.
Surgical Equipment & Devices
- Minimally or Less Invasive
- Surgical Equipment & Devices
- Therapeutic Areas
- Musculoskeletal & Connective Tissue Disorders
- Neurology, Nervous System
- Spotlight Surgical Inc.
- North America
- Parent & Subsidiaries
- Invuity Inc.
- Senior Management
Scott Flora, Interim Pres. & CEO
James Mackaness, CFO
Alex Vayser, CTO
Joe Guido, VP, Commercial Mktg. & Bus. Dev.
- Contact Info
Phone: (415) 655-2100
444 De Haro St.
San Francisco, CA 94107
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.